Capricor Therapeutics, Inc. · NASDAQ:CAPR

Capricor Therapeutics — Q2 2017 Earnings Presentation

7 slides from Capricor Therapeutics's earnings presentation, Aug 10, 2017

  1. Slide 1: Capricor Therapeutics Second Quarter 2017 Corporate Update

    Capricor Therapeutics Second Quarter 2017 Corporate Update August 10, 2017

  2. Slide 2: Forward-Looking Statements

    Forward - Lookin g Statements Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates ; the initiation, conduct, size, timing and results of discovery efforts and clinical trials ; the pace of enrollment of clinical trials ; plans re

  3. Slide 3: CDCs Possess Broad Bioactivity

    CDCs Possess Broad Bioactivity Property Refer ences x Regenerative 1,2 x Anti - fibrotic 1 - 4 x Anti - apoptotic 3 - 5 x Angiogenic 1,6 x Anti - inflammatory 9 x Immunomodulatory 9,10 1. Smith et al. Circulation 2007 ; 115 :896 - 908. 2. Makkar et al. Lancet 2012 ; 379 :895 - 904. 3. Tseliou et al.

  4. Slide 4: Evolution of Capricor's Science and Clinical Development

    Retention and Engraftment ( c - Kit) Paracrine (growth factors) Exosomes (RNA, proteins ) Evolution of Capricor’s Science and Clinical Development Elucidation of Mechanism Progression of Clinical Trials  F ibrosis,  A poptosis,  Regeneration  I nflammation,  Oxidative Stress,  Mitochondrial St

  5. Slide 5: DMD Pathophysiology

    DMD Pathophysiology Adapted from Guiraud et al. Curr Opin Pharmacol 2017 ; 34 :36 - 48. Dystrophin deficiency Loss of membrane stability Inflammation Impaired Regeneration Fibrosis Necrosis Muscle Degeneration Oxidative Stress Mitochondrial Dysfunction Muscle Wasting Loss of Function 5

  6. Slide 6: Cardiac and Ambulatory Effects of CDCs in mdx Model

    6 0 200 400 600 800 1000 BL 3 4 5 6 7 8 9 10 11 12 WT Mdx+CDC Mdx+Vehicle 30 40 50 60 70 80 90 WT Mdx+CDC Mdx+Vehicle *** * * * * Ejection Fraction (%) # # # # # # # # # Distance (m) Weeks # Injection #2 Injection #1 # p<0.005 vs. Mdx+CDC * p<0.05 vs. Mdx+CDC ; *** p<0.005 vs. Mdx+CDC Ambulatory cap

  7. Slide 7: CAP-1002's Activities in DMD… and Potentially Beyond

    Inflammation Duchenne Muscular D ystrophy CAP - 1002 Oxidative Stress Mitochondrial Dysfunction Apoptosis Fibrosis potential to address a variety of rare pediatric diseases other muscular dystrophies limb - girdle disorders cystic fibrosis CAP - 1002’s Activities in DMD… and Potentially Beyond 7

Capricor Therapeutics — Q2 2017 Earnings Presentation on 6ix